ConductScience.org, home

Paper · 41372167

SLFN11 counteracts the RFWD3-PRIMPOL DNA damage tolerance axis to restrain gapped DNA synthesis in response to replication stress.

Coleman KE and 7 others. Nat Commun, 2025. Cited by 4 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. SLFN11 counteracts the RFWD3-PRIMPOL DNA damage tolerance axis to restrain gapped DNA synthesis in response to replication stress. Papers, record 41372167. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41372167

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
SLFN11 counteracts the RFWD3-PRIMPOL DNA damage tolerance axis to restrain gapped DNA synthesis in response to replication stress.
PubMed
Journal
Nat Commun
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2025-12-14
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Coleman KEKate E
2Shin DWDong-Woohttps://orcid.org/0009-0003-5909-972X
3Goehring LLiana
4Szeitz BBeata
5Fenyö DDavid
6Rothenberg EElihttps://orcid.org/0000-0002-1382-1380
7Poirier JTJohn Thttps://orcid.org/0000-0001-9795-5644
8Huang TTTony Thttps://orcid.org/0000-0001-9291-5002

Source PubMed

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DNA DamageMajor topic
DNA ReplicationMajor topic
DNA-Directed DNA PolymeraseMajor topic
DNA PrimaseMajor topic
Multifunctional EnzymesMajor topic
Ubiquitin-Protein LigasesMajor topic
Nuclear ProteinsMajor topic
Humans
DNA
DNA Damage Tolerance

Source PubMed

Grants10

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA016087NCI NIH HHSUnited StatesP30CA016087PubMed and NIHNIH RePORTER
P01CA288368U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)P01CA288368PubMed and NIHNIH RePORTER
R35 GM139610NIGMS NIH HHSUnited StatesR35GM139610PubMed and NIHNIH RePORTER
P01 CA288368NCI NIH HHSUnited StatesP01CA288368PubMed and NIHNIH RePORTER
R35 GM134947NIGMS NIH HHSUnited StatesR35GM134947PubMed and NIHNIH RePORTER
ES031658U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS)R01ES031658PubMed and NIHNIH RePORTER
R01 AI153040NIAID NIH HHSUnited StatesR01AI153040PubMed and NIHNIH RePORTER
R01 ES031658NIEHS NIH HHSUnited StatesR01ES031658PubMed and NIHNIH RePORTER
P01 CA247773NCI NIH HHSUnited StatesP01CA247773PubMed and NIHNIH RePORTER
GM139610U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)R35GM139610PubMed and NIHNIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References98

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134,624,216Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells.Mol Cell2021https://conductscience.org/library/papers/34624216PubMed
232,391,871E3 ligase RFWD3 is a novel modulator of stalled fork stability in BRCA2-deficient cells.J Cell Biol2020https://conductscience.org/library/papers/32391871PubMed
331,676,232PRIMPOL-Mediated Adaptive Response Suppresses Replication Fork Reversal in BRCA-Deficient Cells.Mol Cell2020https://conductscience.org/library/papers/31676232PubMed
438,875,319Schlafen 11 triggers innate immune responses through its ribonuclease activity upon detection of single-stranded DNA.Sci Immunol2024https://conductscience.org/library/papers/38875319PubMed
538,502,677SMARCAL1 ubiquitylation controls its association with RPA-coated ssDNA and promotes replication fork stability.PLoS Biol2024https://conductscience.org/library/papers/38502677PubMed
638,058,754Further Evidence for RFWD3 Gene Causing Fanconi Anemia Complementation Group W: Detailed Clinical Report of the Second Case in the Literature.Mol Syndromol2023https://conductscience.org/library/papers/38058754PubMed
733,863,777SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243.Cancer Res2021https://conductscience.org/library/papers/33863777PubMed
834,508,659REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps.Mol Cell2021https://conductscience.org/library/papers/34508659PubMed
923,341,130A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.EMBO Mol Med2013https://conductscience.org/library/papers/23341130PubMed
1030,753,225SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing.PLoS One2019https://conductscience.org/library/papers/30753225PubMed

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42,909,555DPP9 modulates RPA1 stability and temozolomide sensitivity through RFWD3 Nuclear localization in glioma.Cell Oncol (Dordr)2026https://conductscience.org/library/papers/42909555PubMed
42,615,306RFWD3: A pivotal E3 ubiquitin ligase in DNA damage response, non-neoplastic disorders and multi-system tumorigenesis.Sci Prog2026https://conductscience.org/library/papers/42615306PubMed
42,215,448PHF20 stabilizes the GAS7-F-actin axis to drive DNA damage repair and chemoresistance in cutaneous squamous cell carcinoma.Cell Death Dis2026https://conductscience.org/library/papers/42215448PubMed
42,098,304SLX4IP limits replication stress globally and at ALT telomeres.EMBO J2026https://conductscience.org/library/papers/42098304PubMed
42,092,629Molecular Determinants of Response and Rational Drug Combinations for Antibody-Drug Conjugates (ADCs) with Topoisomerase I (TOP1) Inhibitor Payloads.J Mol Biol2026https://conductscience.org/library/papers/42092629PubMed
41,991,718Topoisomerase I inhibitor antibody-drug conjugates in breast cancer: the relevance of the DNA damage response to resistance, response, and combination treatment strategies.Breast Cancer Res Treat2026https://conductscience.org/library/papers/41991718PubMed

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
DNAH81,769PubTator's text mininghttps://conductscience.org/library/genes/1769NCBI Gene
PRIMPOL201,973PubTator's text mininghttps://conductscience.org/library/genes/201973NCBI Gene
RFWD355,159PubTator's text mininghttps://conductscience.org/library/genes/55159NCBI Gene
SLFN1191,607PubTator's text mininghttps://conductscience.org/library/genes/91607NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41372167

GET https://conductscience.org/api/papers/v1/41372167/references?page=2